Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

SAN FRANCISCO (Thomson Financial) – Alfacell Corp. late Wednesday said results from its Phase IIIB clinical trial for Onconase, which was being studied as a potential treatment for unresectable malignant mesothelioma, didn’t meet the trial’s primary endpoint.

The Somerset, N.J.-based biopharmaceutical company said a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen. Alfacell said it will submit a new drug application to the Food and Drug Administration for the treatment of this patient population.

The Phase IIIB trial was designed to show a statistically significant improvement in overall survival for patients treated with a combination of onconase plus doxorubicin versus patients treated with doxorubicin alone.

The stock closed the regular session up 5 cents at $1.70.

This entry was posted on Thursday, May 29th, 2008 at 9:39 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.